Ipsen Reports Strong First Quarter 2017 Sales Growth Of 19,1%
PARIS--(BUSINESS WIRE)--Regulatory News:
“After the successful closing of the Onivyde® transaction, our largest acquisition to date, we are focused on the successful execution of the Onivyde® and Cabometyx® launches. These two important products strengthen our presence in Oncology and will contribute meaningfully to our top-line growth and profitability in the coming years.”
Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven pharmaceutical group, today announced sales for the first quarter of 2017.
First quarter 2017 unaudited IFRS consolidated sales
| (in million euros) | Q1 2017 | Q1 2016 |
% Change at |
|||
| Specialty Care | 366.5 | 288.1 | 25.4% | |||
| Consumer Healthcare | 71.6 | 73.9 | -5.3% | |||
| Group Sales | 438.0 | 362.0 | 19.1% |